News



  • Valneva Announces the Availability of Documentation for its Meetings of Shareholders2017-06-08

    Valneva Announces the Availability of Documentation for its Meetings of Shareholders

    Lyon (France), June 8, 2017 – The Shareholders of Valneva SE (“Valneva” or “the Company”), are invited to participate in the Company’s Combined General Meeting to be held on June 29, 2017 at 2:30 p.m. CET, at the Novotel Lyon Confluence, 3 rue Paul Montrochet, 69002 Lyon, France. The Combined General Meeting will follow a Special Meeting of Convertible Preferred Share holders to be held at the same location at 2:00 p.m. that same day.

    The preliminary notice of meetings containing the agenda, the proposed resolutions and instructions for participation and voting was published in the Bulletin des Annonces Légales Obligatoires (BALO) on May 22, 2017. Documents and information relating to the meetings are available here.

    PDF Download
  • Valneva to Present at Jefferies 2017 Global Healthcare Conference in New York2017-06-06

    Valneva to Present at Jefferies 2017 Global Healthcare Conference in New York

    Lyon (France), June 06, 2017 – Valneva SE (“Valneva” or “the Company”), a fully integrated, commercial stage biotech company focused on developing innovative lifesaving vaccines, today announced that Thomas Lingelbach, President & Chief Executive Officer will provide a corporate presentation at the Jefferies 2017 Global Healthcare Conference in New York on Thursday, June 8, 2017 at 10:30 AM EDT.

    PDF Download
    auf Deutsch lesen
  • Valneva Reports Strong Q1 Revenue Growth and Positive EBITDA; Reaffirms Financial Guidance and Pipeline Outlook for 20172017-05-11

    Valneva Reports Strong Q1 Revenue Growth and Positive EBITDA Reaffirms Financial Guidance and Pipeline Outlook for 2017

    Robust Q1 financial results – confirming financial self-sustainability strategy
    + Total revenues and grants of €29.1 million in Q1 2017 (vs €24.7 million in Q1 2016) driven by a strong increase in vaccine sales;
    + Q1 product sales performance up 26.7% compared to Q1 2016, mainly driven by IXIARO® sales to the US military and strong sales in the travel market;
    + EBITDA of €3.4 million and operating profit of €0.5 million in Q1 2017 compared to an operating loss of €2.7 million in Q1 2016;
    + Net loss reduced to €1.7 million in Q1 2017 compared to a net loss of €5.0 million in Q1 2016;
    + Cash position at €45.2 million at end of March 2017.

    Press release
    Financial report
    Analyst presentation
    Webcast link
    auf Deutsch lesen
  • Valneva Announces Signing of a New EB66® Commercial License with Bavarian Nordic2017-04-18

    Valneva Announces Signing of a New EB66® Commercial License with Bavarian Nordic

    • Valneva’s EB66® cell-line licensed to Bavarian Nordic for MVA-BN® based product candidates
    • Valneva to support process development

    Lyon (France), April 18, 2017 - Valneva SE (“Valneva” or “the Company”), a fully integrated, commercial stage biotech company focused on developing innovative lifesaving vaccines, today announced that it has entered into a commercial agreement with Danish biotech company Bavarian Nordic (OMX: BAVA, OTC:BVNRY), for the production of poxvirus-based vaccines using Valneva´s EB66® cell-line technology.

    PDF Download
    auf Deutsch lesen
  • Valneva to Present at the 17th World Vaccine Congress in Washington D.C.2017-04-10

    Valneva to Present at the 17th World Vaccine Congress in Washington D.C.

    Lyon (France), April 10, 2017 – Valneva SE (“Valneva” or “the Company”), a leading pure play vaccine company, announced today that it will be holding two presentations on Lyme disease and mosquito-transmitted diseases on April 11, 2017 at the 17th World Vaccine Congress in Washington DC.

    PDF Download
    auf Deutsch lesen
  • Valneva Reports Best Financial Results in the Company’s History with its First Year of Positive EBITDA in 20162017-03-23

    Valneva Reports Best FY Results in the Company’s History with its First Year of Positive EBITDA in 2016

    The Company expects to continue showing a strong financial performance in 2017

    • Total revenues and grants of €97.9 million in 2016 (vs €83.3 million in 2015) driven mainly by a 73.1% increase in IXIARO®/JESPECT® revenues;
    • Valneva reported a positive EBITDA of €2.8 million in 2016 (vs. an EBITDA loss of €8.5 million in 2015);
    Lyon (France), March 23, 2017 – Valneva SE (“Valneva” or “the Company”), a fully integrated, commercial stage biotech company focused on developing innovative lifesaving vaccines, reported today its fourth quarter and full year financial results ending December 31, 2016. The annual financial report including the consolidated financial statements 2016 are available on the Company’s website www.valneva.com.

    A webcast for financial analysts, fund managers, investors and journalists will be held today at 2:00 pm (CET). A replay will be available on the Company’s website. Please refer to this link.

    PDF Download
    auf Deutsch lesen
  • Valneva Announces Publication of its Registration Document2017-03-23

    Valneva Announces Publication of its Registration Document

    Lyon (France), March 23, 2017 – Valneva SE (“Valneva” or “the Company”), a fully integrated, commercial stage biotech company focused on developing innovative lifesaving vaccines, announces today the publication of its 2016 Registration Document (“Document de Référence”), filed with the French Financial Market Authority (“Autorité des Marchés Financiers”) under the filing number D.17-0205 on March 22, 2017.

    PDF Download
  • Valneva Reports Strong Q4 and FY 2016 Business Performance; Expects Further Growth in Sales and EBITDA, R&D Progress in 20172017-02-23

    Valneva Reports Strong Q4 and FY 2016 Business Performance;
    Expects Further Growth in Sales and EBITDA, R&D Progress in 2017

    The Company today announced its unaudited FY 2016 revenues and cash-balance, estimated EBITDA and 2017 outlook

    Lyon (France), February 23, 2017 – Valneva SE (“Valneva” or “the Company”), a fully integrated, commercial stage biotech company focused on developing innovative lifesaving vaccines, published today its unaudited revenues and cash balance, and estimated EBITDA for the fourth quarter and the full year ended December 31, 2016. Audited full year financial results are scheduled to be released on March 23, 2017.

    PDF Download
    auf Deutsch lesen
  • Valneva Supports World Encephalitis Day on February 22, 20172017-02-17

    Valneva Supports World Encephalitis Day on February 22, 2017 

    WED_logo.jpg

    As the manufacturer and supplier of IXIARO® – the only licensed and recommended Japanese encephalitis (JE) vaccine in the US and Europe, Valneva SE is proud to support The Encephalitis Society to raise the awareness of the impact of encephalitis on World Encephalitis Day (WED). Encephalitis, a swelling of the brain, is a devastating condition which affects 500,000 people globally each year.

    PDF Download
  • Valneva Announces a New Research License Agreement with MSD Animal Health for the Development of Vaccines in the EB66® Cell Line2017-01-05

    Valneva Announces a New Research License Agreement with MSD Animal Health for the Development of Vaccines in the EB66® Cell Line

    Lyon (France), January 5, 2017 – Valneva SE (“Valneva” or “the Company”), a fully integrated, commercial stage biotech company focused on developing innovative life-saving vaccines, today announced that it has signed a research license agreement with MSD Animal Health, known as Merck Animal Health in the United States and Canada.

    PDF Download
    auf Deutsch lesen
Please update your browser...